Abstract: A fibrate self-emulsifying oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate, derivative of fenofibrate or mixtures thereof dissolved in a fibrate solubilizer selected from N-alkyl derivative of 2-pyrrolidone, mono- or di- or polyethylene glycol monoethers, C8-12 fatty acid mono- or di-esters of propylene glycol, or combinations thereof, one or more surfactants and optionally one or more stabilizers useful in the treatment of hypercholesterolaemia or hypertriglyceridaemia in mammals in the fed or fasted state.
Type:
Grant
Filed:
June 27, 2003
Date of Patent:
April 4, 2006
Assignee:
Shire Laboratories, Inc.
Inventors:
Likan Liang, Amir H. Shojaei, Scott A. Ibrahim, Beth A. Burnside
Abstract: A formulation for a stabilized capsule for oral administration of a hydrophobic pharmaceutically active agent; comprising a non-aqueous solubilizer selected from 2-pyrrolidone, N-alkylpyrrolidones and combinations thereof; and a capsule stabilizing agent selected from mono-, di- and triglycerides, mono- and di-fatty esters of polyethylene glycol, fatty acids and combinations thereof wherein capsule integrity is maintained for at least 24 hours is disclosed.
Type:
Grant
Filed:
December 20, 2002
Date of Patent:
March 14, 2006
Assignee:
Shire Laboratories, Inc.
Inventors:
Amir H. Shojaei, Scott A. Ibrahim, Beth A. Burnside